1. Multi-Analyte, Genetic, and Thrombogenic Markers of Atherosclerosis (The MAGMA STUDY)
The purpose of this study is to find a correlation between certain blood markers and the growth of the plaques, regardless of the presence of the classic risk factors for atherosclerosis. If we prove our hypothesis, we will be one step closer to predicting the extent of atherosclerosis by performing certain blood tests.
2. A prospective, Multi-center, Randomized, Double-blind Trial to Assess the Effectiveness and Safety of 12 Versus 30 Months of Dual Antiplatelet Therapy (DAPT) in Subjects Undergoing Percutaneous Coronary Intervention (PCI) with Either Drug-Eluting Stent (DES) or Bare Metal Stent (BMS) Placement for the Treatment of Coronary Artery Lesions (DAPT Study)
The aim of DAPT study is to identify the optimal duration of dual antiplatelet therapy in subjects who undergo stenting procedures.
3. SWITCH 600/60 Study
The aim of the study is to compare platelet reactivity in patients receiving a loading dose of clopidogrel and a reloading dose of prasugrel to patients receiving only a loading dose of prasugrel.
4. A Phase 2a, Multi-center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112 in Patients with Stable Atherothrombotic Disease
Reconstituted high density lipoprotein used in patients with acute coronary syndrome (ACS) may reduce atherosclerotic plaque burden, thereby reducing the risk of recurrent cardiovascular events. This study is a multi-center, randomized, placebo-controlled, single ascending dose study in patients with stable atherothrombotic disease in whom the safety and pharmacokinetic profile of CSL112 will be assessed.
5. Pilot Study Evaluating Alterations in Thrombogenecity and Platelet Reactivity Following Lower Extremity Arthroplasty
The aim of this pilot study is to assess potential changes in thrombogenecity by using measures of coagulability and platelet reactivity following elective surgery for lower extremity arthroplasty.
6. A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Effects of Ranolazine on Major Adverse Cardiovascular Events in Subjects with a History of Chronic Angina Who Undergo Percutaneous Coronary Intervention with Incomplete Revascularization
Evaluate the efficacy of ranolazine, as compared with the placebo, when used as part of standard medical therapy in chronic angina subjects with incomplete revascularization post-percutaneous coronary intervention (PCI) on the composite of ischemia riven revascularization or ischemia-driven hospitalization without revascularization.
7. Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High-Risk for Vascular Outcomes – the ACCELERATE Study
The purpose of this study is to test if evacetrapib 130 mg daily, in comparison to a placebo, reduces the incidence of cardiovascular death, myocardial infarction, stroke, coronary revascularization or hospitalization for unstable angina in high-risk vascular disease (HRVD) patients. In addition, it’s designed to test if evacetrapib 130 mg daily in HRVD patients, when compared to a placebo, increases high-density lipoprotein-cholesterol (HDL-C) at 3 months after randomization and decreases low-density lipoprotein-cholesterol (LDL-C) at 3 months after randomization.
8. A Pharmacodynamic Evaluation of Switching from Ticagrelor to Prasugrel in Subjects with Stable Coronary Artery Disease: 2nd Switching Antiplatelet Agents (SWAP 2)
The purpose of this study is to compare the effects of prasugrel and ticagrelor on platelet aggregation (platelets clumping together) in subjects with stable coronary artery disease (CAD) who are treated with prasugrel, 10 mg, once a day or ticagrelor, 90 mg, twice a day, after 7 days of a randomized study treatment.
9. ALERTS (AngelMed for Early Recognition and Treatment of STEMI) Study
The purpose of the study is to evaluate the effectiveness of the AngelMed Guardian System as compared with the standard of care in reducing the incidence of the composite of death, new Q-wave MI and presentation > 2 hours for thrombotic coronary occlusion events among subjects at a high-risk of recurrent myocardial infarction.